

EMPAGLIFLOZIN tablets (Jardiance®) for treating chronic heart failure with reduced ejection fraction

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of EMPAGLIFLOZIN tablets (Jardiance®) for treating chronic heart failure with reduced ejection fraction

GREY

Empagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction^[1].

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of chronic heart failure with reduced ejection fraction should continue to follow national guidance, local pathways and local formulary choices.

- > NICE Guideline [NG106]: [Chronic heart failure in adults: diagnosis and management](#) (12 September 2018)
- > Pan Mersey APC formulary: [chapter 2 cardiovascular system](#)

References

1. Boehringer Ingelheim Ltd. Summary of Product Characteristics; [Jardiance 10mg film coated tablets](#), 30 July 2021. Accessed online 23 September 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.